Indoco Remedies gets USFDA nod for Succinylcholine Chloride Injection
The product is being used for some patients infected with Coronavirus (COVID-19)
Mumbai: Indoco Remedies has received USFDA approval for Succinylcholine Chloride Injection, USP 200 mg / 10 ml (20 mg/ml) multi-dose vial, therapeutically equivalent to the Reference Listed Drug (RLD) Quelicin Injection of Hospira, Inc.
Succinylcholine Chloride Injection is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
The US market size of Succinylcholine Chloride Injection is 72 million USD (6 million vials), as per IMS data for the year ending March 2020.
The product is being used for some patients infected with Coronavirus (COVID-19).
Commenting on this positive outcome, Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd. said, "The receipt of this USFDA approval, in a record time of just 4 months from the date of filing ANDA, is very encouraging. It brings an enormous opportunity to Indoco to serve the patients in these trying times."
Read also: COVID 19: Natco Pharma supports Columbia University trials for CQ tablets to prevent infections
